Biotech Updates: Acrivon CLIA Lab, Lilly M&A Spree, Defence Radiopharma COO
Aug 17, 2026
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
News Related to Small Molecule Inhibitor
Related coverage linked through entity extraction aliases.
Biogen and Denali Discontinue BIIB122 Development in Idiopathic Parkinson's After Phase 2b LUMA Miss
Jul 28, 2026
BIIB122 failed to slow Parkinson's progression in the Phase 2b LUMA study, missing primary and secondary endpoints. Biogen and Denali will discontinue the drug in idiopathic Parkinson's disease; Denali continues the BEACON study in LRRK2 carriers.
Astellas ends ASP5502 Sjögren’s trial as Novartis’ ianalumab gains FDA breakthrough tag
Apr 22, 2026
Astellas terminated its phase 1 ASP5502 study in Sjögren’s syndrome as Novartis said the FDA granted breakthrough therapy designation to ianalumab. Novartis plans global regulatory submissions from early 2026 after positive phase III data.
Eli Lilly Acquires Rights to CSL's IL-6 Inhibitor in $100M Deal
Mar 26, 2026
Eli Lilly has acquired rights to CSL's IL-6 inhibitor clazakizumab in a $100 million deal, expanding its cardiometabolic pipeline. The monoclonal antibody targets chronic inflammation, particularly in cardiovascular conditions. This move follows Lilly's successful obesity and diabetes drugs that drove $65.1 billion in 2025 revenue.